You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Quidel reported preliminary fourth quarter revenues of $808 million to $810 million, compared to $152.2 million in Q4 2019.
The collaboration builds on an oligonucleotide supply agreement the partners signed in 2019 for Clear Labs' nanopore sequencing-based food safety testing.
The test will identify more than 100 pathogens, as well as drug resistance in viruses and bacteria.
The deal will enable PerkinElmer to grow its infectious disease testing portfolio to include latent tuberculosis detection, it said.
The partners have already identified cases in the US of the novel, highly transmissible SARS-CoV-2 variant that was first reported in the UK.
The test has been validated on many widely available RT-PCR instruments including ones from Thermo Fisher Scientific, Roche, and Qiagen.
The agency has alerted providers to adhere to testing instructions. The firm, meanwhile, disagrees with FDA's assessment.
The company, known for providing hereditary risk testing for cancer and cardiovascular conditions, has expanded into SARS-CoV-2 testing.
The system is based on GNA's proprietary pulsed control amplification technology, which uses short electrical pulses to drive rapid amplification cycles.
The SARS-CoV-2 test, which runs on Cepheid's GeneXpert systems, is to detect SARS-CoV-2 nucleic acid in upper respiratory specimens such as nasal swabs.
The Solana SARS-CoV-2 test can be run in batches of 11 samples, with minimum hands on time, no extraction, and results in approximately 25 minutes.
Xprize said it selected the finalists from 219 semifinalists after conducting blind proficiency testing and judging a questionnaire reflecting each team's qualifications.
An analysis of SARS-CoV-2 genomes from early COVD-19 patients in Scotland shows the virus was introduced there multiple times, typically from continental Europe.
Q2 Solutions will run Adaptive's NGS-based immune cell receptor profiling assay for its pharma and biotech clients, potentially in COVID-19 vaccine trials.
The PCR-based test is designed to detect SARS-CoV-2 nucleic acid in upper respiratory specimens such as anterior nasal swabs collected by a healthcare provider.
Osang is seeking US Food and Drug Administration Emergency Use Authorization for its PCR-based SARS-CoV-2 diagnostic kit and plans to distribute it to US airports.
While SARS-CoV-2 test demand will likely remain strong well into 2021, the question of what to do with the built-up capacity in a post-COVID-19 environment looms.
Toronto-based DMark Biosciences will provide the UgenTec FastFinder PCR analysis software to molecular diagnostic labs across Canada.
The firm claims a rapid isothermal test has an LoD of 20 viral copies per milliliter while a saliva-based PCR test has an LoD of 2 copies per milliliter.
The PCR-based panel is designed to simultaneously detect SARS-CoV-2, influenza A and B, and respiratory syncytial virus, with results in less than two hours.
The Wall Street Journal reports on gaps in COVID-19 testing affecting less affluent urban areas and rural locations.
According to NBC News, new SARS-CoV-2 variants are making it harder for researchers to model the course of the pandemic.
The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.
In Science this week: single-cell lineage tracing technique applied to study lung cancer metastasis, and more.